Revenue increased from $6,380 in 2024 to $700,508 in 2025, primarily from sales of biologics ($443,750) and medical procedures ($245,600). Net loss increased from $181,067 in 2024 to $395,464 in 2025, contributing to an accumulated deficit of $15,973,482 as of December 31, 2025. The company's auditor raised substantial doubt about its ability to continue as a going concern. Disclosure controls and procedures, as well as internal control over financial reporting, were deemed ineffective as of December 31, 2025, citing a lack of formal documentation, segregation of duties, and formal review processes. ADIA Nutrition transitioned from a 'Shell Company' status to an operating company on June 30, 2024, following the acquisition of Biolete LLC and the establishment of medical clinics (Adia Med) and product labs (Adia Labs). The company successfully settled a lawsuit on May 5, 2025, resulting in the retirement of 15,495,165 common shares and 10,000,000 Series A Preferred Shares that were deemed improperly acquired. ADIA Nutrition operates in the stem cell therapy sector, focusing on Autologous Hematopoietic Stem Cell Transplantation (AHSCT) and Umbilical Cord Stem Cell (UCB-SC) treatments, and also has an 18% equity position in Cement Factory, LLC for supplements.